Aldeyra Therapeutics, Inc. (ALDX) financial statements (2022 and earlier)

Company profile

Business Address 131 HARTWELL AVENUE
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:229,79177,85844,42647,35742,94724,90027,600
Cash and cash equivalents229,79177,85844,42647,35720,02312,01514,649
Short-term investments  28,939 22,92312,89812,942
Other undisclosed cash, cash equivalents, and short-term investments  (28,939)  (13)9
Other undisclosed current assets2,9625,20130,74347,4121,019231488
Total current assets:232,75383,05975,16994,76943,96625,13128,088
Noncurrent Assets
Operating lease, right-of-use asset352233201
Property, plant and equipment3260148235435680
Other undisclosed noncurrent assets   87166 36
Total noncurrent assets:38429334932220956117
TOTAL ASSETS:233,13783,35375,51895,09144,17525,18828,205
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11,5438,51612,6818,4733,2372,2222,038
Accounts payable1,0203828083,0521,001275851
Accrued liabilities10,5238,13511,8735,4212,2361,9461,186
Debt 3,660226 1167878
Other undisclosed current liabilities230233     
Total current liabilities:11,77312,40912,9088,4733,3542,2992,115
Noncurrent Liabilities
Long-term debt and lease obligation15,62911,43414,528 1,2201,2391,211
Long-term debt, excluding current maturities15,50411,43414,528 1,2201,2391,211
Operating lease, liability125  
Other undisclosed noncurrent liabilities(125)      
Total noncurrent liabilities:15,62911,43414,528 1,2201,2391,211
Total liabilities:27,40223,84427,4368,4734,5743,5383,326
Stockholders' equity
Stockholders' equity attributable to parent205,73659,50948,08286,61839,60121,65024,878
Common stock58392926191310
Additional paid in capital500,369296,386247,410225,136139,24298,93883,479
Accumulated other comprehensive income (loss)  6(9)(18)0(8)
Accumulated deficit(294,692)(236,916)(199,362)(138,535)(99,642)(77,301)(58,602)
Total stockholders' equity:205,73659,50948,08286,61839,60121,65024,878
TOTAL LIABILITIES AND EQUITY:233,13783,35375,51895,09144,17525,18828,205

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Operating expenses(56,220)(34,667)(56,507)(39,699)(22,488)(18,696)(11,989)
Other undisclosed operating loss (1,754)(6,568)    
Operating loss:(56,220)(36,421)(63,074)(39,699)(22,488)(18,696)(11,989)
Nonoperating income (expense)(1,557)(1,612)938806148(3)(101)
Investment income, nonoperating1852921,54195326110211
Interest and debt expense(1,742)(1,904)(604)(147)(113)(106)(112)
Loss from continuing operations before equity method investments, income taxes:(59,518)(39,937)(62,741)(39,040)(22,454)(18,805)(12,203)
Other undisclosed income from continuing operations before income taxes1,7421,904604    
Loss from continuing operations before income taxes:(57,776)(38,033)(62,137)(39,040)(22,454)(18,805)(12,203)
Income tax benefit 4791,310    
Net loss:(57,776)(37,554)(60,827)(39,040)(22,454)(18,805)(12,203)
Other undisclosed net income attributable to parent   147113106112
Net loss available to common stockholders, diluted:(57,776)(37,554)(60,827)(38,893)(22,341)(18,699)(12,090)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(57,776)(37,554)(60,827)(39,040)(22,454)(18,805)(12,203)
Other comprehensive income (loss) (6)159(18)8(8)
Comprehensive loss:(57,776)(37,560)(60,812)(39,031)(22,472)(18,796)(12,211)
Other undisclosed comprehensive income, net of tax, attributable to parent   147113106112
Comprehensive loss, net of tax, attributable to parent:(57,776)(37,560)(60,812)(38,885)(22,359)(18,691)(12,099)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: